UY39579A - COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS - Google Patents

COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS

Info

Publication number
UY39579A
UY39579A UY0001039579A UY39579A UY39579A UY 39579 A UY39579 A UY 39579A UY 0001039579 A UY0001039579 A UY 0001039579A UY 39579 A UY39579 A UY 39579A UY 39579 A UY39579 A UY 39579A
Authority
UY
Uruguay
Prior art keywords
cgas
compounds
treatment
composition
conditions associated
Prior art date
Application number
UY0001039579A
Other languages
English (en)
Inventor
David Carcache
Florian Gruber
Danilo Guerini
Martin Gunzenhauser
Richard Heng
Francesca Perruccio
Oliver Simic
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39579A publication Critical patent/UY39579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente revelación se refiere a un compuesto de Formula (I): o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo, donde R1 hasta R8 inclusive son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
UY0001039579A 2020-12-22 2021-12-20 COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS UY39579A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063128949P 2020-12-22 2020-12-22

Publications (1)

Publication Number Publication Date
UY39579A true UY39579A (es) 2022-07-29

Family

ID=79164465

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039579A UY39579A (es) 2020-12-22 2021-12-20 COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS

Country Status (19)

Country Link
US (1) US20230085472A1 (es)
EP (1) EP4267564A1 (es)
JP (1) JP2024502258A (es)
KR (1) KR20230124665A (es)
CN (1) CN116635382A (es)
AR (1) AR124443A1 (es)
AU (1) AU2021404953A1 (es)
CA (1) CA3202212A1 (es)
CL (1) CL2023001859A1 (es)
CO (1) CO2023007954A2 (es)
CR (1) CR20230282A (es)
DO (1) DOP2023000129A (es)
EC (1) ECSP23045506A (es)
IL (1) IL303913A (es)
MX (1) MX2023007467A (es)
PE (1) PE20240229A1 (es)
TW (1) TW202241873A (es)
UY (1) UY39579A (es)
WO (1) WO2022137085A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235809A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Cgas inhibitors
WO2024083773A1 (en) 2022-10-18 2024-04-25 Glaxosmithkline Intellectual Property Development Limited Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors
US20240246979A1 (en) 2022-12-21 2024-07-25 Eli Lilly And Company cGAS INHIBITORS
WO2024183726A1 (en) * 2023-03-06 2024-09-12 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
US8053457B2 (en) * 2007-03-29 2011-11-08 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
CA2971755A1 (en) 2014-12-22 2016-06-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
JP7286679B2 (ja) * 2018-02-05 2023-06-05 ザ ロックフェラー ユニバーシティー 自己炎症性疾患を治療するためのｃＧＡＳの２，３，４，５－テトラヒドロ－１Ｈ－ピリド［４，３－ｂ］インドール阻害剤

Also Published As

Publication number Publication date
US20230085472A1 (en) 2023-03-16
IL303913A (en) 2023-08-01
CR20230282A (es) 2023-07-12
DOP2023000129A (es) 2023-07-16
MX2023007467A (es) 2023-07-04
JP2024502258A (ja) 2024-01-18
KR20230124665A (ko) 2023-08-25
AU2021404953A9 (en) 2024-02-08
CA3202212A1 (en) 2022-06-30
PE20240229A1 (es) 2024-02-16
CL2023001859A1 (es) 2024-02-09
CO2023007954A2 (es) 2023-06-30
TW202241873A (zh) 2022-11-01
WO2022137085A1 (en) 2022-06-30
CN116635382A (zh) 2023-08-22
AU2021404953A1 (en) 2023-06-22
EP4267564A1 (en) 2023-11-01
ECSP23045506A (es) 2023-07-31
AR124443A1 (es) 2023-03-29

Similar Documents

Publication Publication Date Title
UY39579A (es) COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
UY38057A (es) Inhibidores de sarcómero cardíaco
PE20180455A1 (es) Compuestos heterociclicos como inhibidores de lsd1
CU20190086A7 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats
CR20110059A (es) Compuestos organicos
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
ECSP21016009A (es) Inhibidores de sarcómeros cardíacos
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
AR116116A1 (es) Proceso para elaborar inhibidores de jak e intermediarios de los mismos
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
UY38618A (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
UY36074A (es) ?derivados de dihidropirrolopirimidina? .
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo